<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222285</url>
  </required_header>
  <id_info>
    <org_study_id>Vayarin_005</org_study_id>
    <nct_id>NCT02222285</nct_id>
  </id_info>
  <brief_title>An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)</brief_title>
  <official_title>An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzymotec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enzymotec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study objective is to evaluate the efficacy of Vayarin_005 on ASD related
      symptoms in children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aberrant Behavior Checklist will be used to asses Autism spectrum symptoms</measure>
    <time_frame>over 14 weeks</time_frame>
    <description>A significant reduction from baseline to endpoint on the Aberrant Behavior Checklist (ABC) compared to patients administered placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity assesment</measure>
    <time_frame>over 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement assesment</measure>
    <time_frame>over 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Rating Scale questionnaire</measure>
    <time_frame>over 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory of Executive function</measure>
    <time_frame>over 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Health Questionnaire</measure>
    <time_frame>over 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Strain Questionnaire</measure>
    <time_frame>over 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events monitoring</measure>
    <time_frame>over 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Autistic Disorder</condition>
  <arm_group>
    <arm_group_label>Sequence 3: placebo/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/placebo consists of placebo for 7 weeks followed by 7 weeks of placebo treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: placebo/ Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sequence 2: placebo/ Treatment , consists of placebo for 7 weeks followed by 7 weeks of treatment with Vayarin_005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence one: Treatment/Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment/Treatment- consists of PS_005 for 7 weeks followed by 7 weeks of additional treatment with Vayarin_005</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Food : Vayarin_005</intervention_name>
    <arm_group_label>Sequence 2: placebo/ Treatment</arm_group_label>
    <arm_group_label>Sequence one: Treatment/Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sequence 3: placebo/placebo</arm_group_label>
    <arm_group_label>Sequence 2: placebo/ Treatment</arm_group_label>
    <other_name>Cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, ages 6-17 inclusive

          2. Must have a valid diagnosis of autism spectrum disorder via a clinical review of the
             DSM-IV, confirmed by Autism Diagnostic Observation Schedule (ADOS)

          3. Clinical Global Impression Scale of Severity of Illness for Pervasive Developmental
             Disorders (CGI-S-PDD) rating of 4 or higher (moderately ill or worse)

          4. IQ &gt;50 evaluated by KBIT-2 or Stanford Binet Fifth Edition

          5. Able, and likely to fully comply with the study procedures and instructions

          6. Subjects with mood, anxiety, or disruptive behavior disorders will be allowed to
             participate in the study provided they do not meet any exclusionary criteria.

          7. Have normal physical examination and laboratory test results at screening. If
             abnormal, the finding(s) must be deemed clinically insignificant by the study
             Clinician.

          8. Parents or legal guardian must be able to read, write and speak English

          9. Parents or legal guardian have given written informed consent to participate in the
             study

        Exclusion Criteria:

          1. The subject is significantly underweight under the 5th percentile or obese above the
             95th percentile

          2. Clinically significant systemic illness including hepatic, renal, gastroenterological,
             metabolic, respiratory, cardiovascular (including ischemic heart disease),
             endocrinologic, neurologic, immunologic, or hematologic disease, as determined by the
             study clinician.

          3. Patients with any primary psychiatric diagnosis other than autism at screening or a
             known genetic syndrome(s) that cause autism.

          4. Suspected or established CNS injury

          5. Change in dosage of psychiatric pharmacotherapy or other medications that have central
             nervous system effects or that affect performance 4 weeks before study initiation and
             throughout the study phase

          6. Use of alpha-agonists, or ADHD medications 4 weeks prior to study initiation and
             throughout the study

          7. Use of dietary supplements, 60 days before study initiation and throughout the study

          8. Change in educational/behavioral interventions within one month prior to participation
             or during the study

          9. A known comorbid psychiatric diagnoses of bipolar I disorder, suicidality, or
             substantial psychotic disorder.

         10. Subject who has participated in another clinical trial within 30 days of screening for
             this trial and/or any experimental treatment for this population

         11. Current history of physical, sexual, or emotional abuse

         12. History of alcohol or substance abuse as defined by DSM-IV criteria

         13. Consumption of &gt;250 mg/day of caffeine

         14. History of allergic reactions or sensitivity to marine products and soy

         15. Has any illness which may jeopardize the participants' health or limit their
             successful trial completion.

         16. Any other reason that, in the opinion of the investigator, prevents the subject from
             participating in the study or compromise the patient safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hollander, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Neuroscience and Treatment Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Neurology and Neurosurgery at St. Barnabas</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Neuroscience and Treatment Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

